Pharma Deals Review, Vol 2002, No 27 (2002)

Font Size:  Small  Medium  Large

Actelion to Market Zavesca in Europe

Business Review Editor

Abstract


Oxford GlycoSciences (OGS) and Actelion singed a binding letter of intent for a European marketing and distribution partnership for OGS’s Zavesca™. Zavesca is an oral formulation of miglustat for the treatment of Type 1 Gaucher disease.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.